Pharmaceutical major GSK plc has announced plans to invest $30 billion in the United States over the next five years, including a new $1.2 billion project focused on manufacturing, artificial intelligence, and advanced digital technologies.
According to the company’s press release issued on Wednesday, the $1.2 billion allocation will be used to construct a biologics flex factory in Pennsylvania, aimed at expanding capacity in biologics production. GSK noted that the project is expected to create new highly skilled jobs in the US while strengthening research, development, and manufacturing across both the US and the UK.
The company also highlighted that with this new initiative, it has now committed nearly $2 billion towards US manufacturing investments in the past year alone. GSK said the broader strategy is aligned with its goal of building a 15,000-strong workforce in the United States over the coming years.
